工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
我们的方法将酶/前药治疗和免疫治疗整合到一个单一的细菌递送系统中，通过提供合理设计的空间控制化学免疫治疗框架，克服了传统疗法的关键局限性。
98.9分
★★★★★
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
受体酪氨酸激酶样孤儿受体作为癌症免疫治疗的潜在靶点
英文原题：Receptor tyrosine kinase-like orphan receptor serves as a potential target in cancer immunotherapy.
查看英文原题
Receptor tyrosine kinase-like orphan receptor serves as a potential target in cancer immunotherapy.
研究概要
受体酪氨酸激酶样孤儿受体（ROR）由 ROR1 和 ROR2 组成，是受体酪氨酸激酶超家族中一个保守的家族，在胚胎发育过程中发挥关键作用，在成人正常组织中表达有限。
中文摘要
受体酪氨酸激酶样孤儿受体（ROR）家族包括ROR1和ROR2，是进化保守的受体酪氨酸激酶超家族成员，在胚胎发育中发挥关键作用，而在成人正常组织中表达有限。然而，ROR在多种血液系统恶性肿瘤和实体瘤中过表达，并参与细胞存活、极性和迁移等过程，因此是癌症免疫治疗的潜在靶点。本综述总结ROR在发育形态发生过程中的表达与结构，以及其通过Wnt5a信号参与癌症的功能，并介绍靶向ROR的癌症免疫治疗策略。
展开英文摘要原文
Receptor tyrosine kinase-like orphan receptor (ROR), consisting of ROR1 and ROR2, is a conserved family of receptor tyrosine kinase superfamily that plays crucial roles during embryonic development with limited expression in adult normal tissues. However, it is overexpressed in a range of hematological malignancies and solid tumors and functions in cellular processes including cell survival, polarity, and migration, serving as a potential target in cancer immunotherapy. This review summarizes the expression and structure of ROR in developmental morphogenesis and its function in cancers associated with Wnt5a signaling and highlights the cancer immunotherapy strategies targeting ROR.
论文信息
- 作者
- Wang J、Li Z、Zhao Q
- 单位
- Cancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR 999078, China.China
- 文献类型
- 综述
- 期刊
- Journal of leukocyte biology2025 Feb 13
- 原文标识
- PubMed 38973261 · DOI 10.1093/jleuko/qiae141